A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors

Roger Leblanc, J. Roy, C. Demers, L. Vu, G. Cantin

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Granulocyte colony-stimulating factor (G-CSF) is used in healthy donors of peripheral blood stem cells (PBSC) for allogeneic transplantation. However, some data have recently suggested that G-CSF may induce a hypercoagulable state, prompting us to study prospectively 22 PBSC donors before and after G-CSF 5 μg/kg twice daily. We sought evidence for changes in the following parameters: platelet count, von Willebrand factor antigen (vWF:Ag) and activity (vWF activity), β-thromboglobulin (β-TG), platelet factor 4 (PF-4), platelet activation markers (GMP-140 and PAC-1), activated partial thromboplastin time (aPTT), prothrombin time (PT), coagulant factor VIII (FVIII:C), thrombin-antithrombin complex (TAT), prothrombin fragment 1 + 2 (F1 + 2), thrombomodulin (TM) and tissue plasminogen activator antigen (tPA:Ag) prior to G-CSF and immediately before leukapheresis. ADP-induced platelet aggregation studies were also performed. G-CSF administration produced only mild discomfort. We found a significant increase in vWF:Ag (from 0.99 ± 0.32 U/ml to 1.83 ± 0.69 U/ml; P < 0.001), in vWF activity (from 1.04 ± 0.34 U/ml to 1.78 ± 0.50 U/ml; P < 0.001) and in FVIII:C (from 1.12 ± 0.37 U/ml to 1.73 ± 0.57 U/ml; P < 0.001) after G-CSF. Of note, four donors with low baseline vWF had a two- to three-fold increase after receiving G-CSF. GCSF had no impact on the platelet count, β-TG, PF-4, GMP-140 or PAC-1. The final% of platelet aggregation decreased from 73 ± 22% to 37 ± 26% after G-CSF (P < 0.001). We found a significant decrease in aPTT after G-CSF (29.9 ± 3.1 s to 28.3 ± 3.3 s; P = 0.004), but the PT was unaffected. In addition, we also observed a significant increase in TAT, F1 + 2 and TM, but not in tPA:Ag. Our data suggest that G-CSF may possibly induce a hypercoagulable state by increasing levels of FVIII:C and thrombin generation. In contrast to this information, we found reduced platelet aggregation after G-CSF administration. The clinical implications of these findings remain unclear and larger studies are definitely required.

Original languageEnglish
Pages (from-to)991-996
Number of pages6
JournalBone Marrow Transplantation
Volume23
Issue number10
StatePublished - Jun 9 1999
Externally publishedYes

Fingerprint

Granulocyte Colony-Stimulating Factor
Hemostasis
Blood Cells
Stem Cells
Prospective Studies
Platelet Aggregation
Platelet Factor 4
Thrombomodulin
P-Selectin
Partial Thromboplastin Time
Prothrombin Time
von Willebrand Factor
Platelet Count
Leukapheresis
Peripheral Blood Stem Cell Transplantation
Coagulants
Homologous Transplantation
Platelet Activation
Factor VIII
Tissue Plasminogen Activator

Keywords

  • Granulocyte colony-stimulating factor
  • Healthy peripheral blood stem cell donors
  • Platelet activation
  • Thrombosis

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. / Leblanc, Roger; Roy, J.; Demers, C.; Vu, L.; Cantin, G.

In: Bone Marrow Transplantation, Vol. 23, No. 10, 09.06.1999, p. 991-996.

Research output: Contribution to journalArticle

Leblanc, Roger ; Roy, J. ; Demers, C. ; Vu, L. ; Cantin, G. / A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. In: Bone Marrow Transplantation. 1999 ; Vol. 23, No. 10. pp. 991-996.
@article{1207f1283756479a9aaea040b5daa14f,
title = "A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors",
abstract = "Granulocyte colony-stimulating factor (G-CSF) is used in healthy donors of peripheral blood stem cells (PBSC) for allogeneic transplantation. However, some data have recently suggested that G-CSF may induce a hypercoagulable state, prompting us to study prospectively 22 PBSC donors before and after G-CSF 5 μg/kg twice daily. We sought evidence for changes in the following parameters: platelet count, von Willebrand factor antigen (vWF:Ag) and activity (vWF activity), β-thromboglobulin (β-TG), platelet factor 4 (PF-4), platelet activation markers (GMP-140 and PAC-1), activated partial thromboplastin time (aPTT), prothrombin time (PT), coagulant factor VIII (FVIII:C), thrombin-antithrombin complex (TAT), prothrombin fragment 1 + 2 (F1 + 2), thrombomodulin (TM) and tissue plasminogen activator antigen (tPA:Ag) prior to G-CSF and immediately before leukapheresis. ADP-induced platelet aggregation studies were also performed. G-CSF administration produced only mild discomfort. We found a significant increase in vWF:Ag (from 0.99 ± 0.32 U/ml to 1.83 ± 0.69 U/ml; P < 0.001), in vWF activity (from 1.04 ± 0.34 U/ml to 1.78 ± 0.50 U/ml; P < 0.001) and in FVIII:C (from 1.12 ± 0.37 U/ml to 1.73 ± 0.57 U/ml; P < 0.001) after G-CSF. Of note, four donors with low baseline vWF had a two- to three-fold increase after receiving G-CSF. GCSF had no impact on the platelet count, β-TG, PF-4, GMP-140 or PAC-1. The final{\%} of platelet aggregation decreased from 73 ± 22{\%} to 37 ± 26{\%} after G-CSF (P < 0.001). We found a significant decrease in aPTT after G-CSF (29.9 ± 3.1 s to 28.3 ± 3.3 s; P = 0.004), but the PT was unaffected. In addition, we also observed a significant increase in TAT, F1 + 2 and TM, but not in tPA:Ag. Our data suggest that G-CSF may possibly induce a hypercoagulable state by increasing levels of FVIII:C and thrombin generation. In contrast to this information, we found reduced platelet aggregation after G-CSF administration. The clinical implications of these findings remain unclear and larger studies are definitely required.",
keywords = "Granulocyte colony-stimulating factor, Healthy peripheral blood stem cell donors, Platelet activation, Thrombosis",
author = "Roger Leblanc and J. Roy and C. Demers and L. Vu and G. Cantin",
year = "1999",
month = "6",
day = "9",
language = "English",
volume = "23",
pages = "991--996",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors

AU - Leblanc, Roger

AU - Roy, J.

AU - Demers, C.

AU - Vu, L.

AU - Cantin, G.

PY - 1999/6/9

Y1 - 1999/6/9

N2 - Granulocyte colony-stimulating factor (G-CSF) is used in healthy donors of peripheral blood stem cells (PBSC) for allogeneic transplantation. However, some data have recently suggested that G-CSF may induce a hypercoagulable state, prompting us to study prospectively 22 PBSC donors before and after G-CSF 5 μg/kg twice daily. We sought evidence for changes in the following parameters: platelet count, von Willebrand factor antigen (vWF:Ag) and activity (vWF activity), β-thromboglobulin (β-TG), platelet factor 4 (PF-4), platelet activation markers (GMP-140 and PAC-1), activated partial thromboplastin time (aPTT), prothrombin time (PT), coagulant factor VIII (FVIII:C), thrombin-antithrombin complex (TAT), prothrombin fragment 1 + 2 (F1 + 2), thrombomodulin (TM) and tissue plasminogen activator antigen (tPA:Ag) prior to G-CSF and immediately before leukapheresis. ADP-induced platelet aggregation studies were also performed. G-CSF administration produced only mild discomfort. We found a significant increase in vWF:Ag (from 0.99 ± 0.32 U/ml to 1.83 ± 0.69 U/ml; P < 0.001), in vWF activity (from 1.04 ± 0.34 U/ml to 1.78 ± 0.50 U/ml; P < 0.001) and in FVIII:C (from 1.12 ± 0.37 U/ml to 1.73 ± 0.57 U/ml; P < 0.001) after G-CSF. Of note, four donors with low baseline vWF had a two- to three-fold increase after receiving G-CSF. GCSF had no impact on the platelet count, β-TG, PF-4, GMP-140 or PAC-1. The final% of platelet aggregation decreased from 73 ± 22% to 37 ± 26% after G-CSF (P < 0.001). We found a significant decrease in aPTT after G-CSF (29.9 ± 3.1 s to 28.3 ± 3.3 s; P = 0.004), but the PT was unaffected. In addition, we also observed a significant increase in TAT, F1 + 2 and TM, but not in tPA:Ag. Our data suggest that G-CSF may possibly induce a hypercoagulable state by increasing levels of FVIII:C and thrombin generation. In contrast to this information, we found reduced platelet aggregation after G-CSF administration. The clinical implications of these findings remain unclear and larger studies are definitely required.

AB - Granulocyte colony-stimulating factor (G-CSF) is used in healthy donors of peripheral blood stem cells (PBSC) for allogeneic transplantation. However, some data have recently suggested that G-CSF may induce a hypercoagulable state, prompting us to study prospectively 22 PBSC donors before and after G-CSF 5 μg/kg twice daily. We sought evidence for changes in the following parameters: platelet count, von Willebrand factor antigen (vWF:Ag) and activity (vWF activity), β-thromboglobulin (β-TG), platelet factor 4 (PF-4), platelet activation markers (GMP-140 and PAC-1), activated partial thromboplastin time (aPTT), prothrombin time (PT), coagulant factor VIII (FVIII:C), thrombin-antithrombin complex (TAT), prothrombin fragment 1 + 2 (F1 + 2), thrombomodulin (TM) and tissue plasminogen activator antigen (tPA:Ag) prior to G-CSF and immediately before leukapheresis. ADP-induced platelet aggregation studies were also performed. G-CSF administration produced only mild discomfort. We found a significant increase in vWF:Ag (from 0.99 ± 0.32 U/ml to 1.83 ± 0.69 U/ml; P < 0.001), in vWF activity (from 1.04 ± 0.34 U/ml to 1.78 ± 0.50 U/ml; P < 0.001) and in FVIII:C (from 1.12 ± 0.37 U/ml to 1.73 ± 0.57 U/ml; P < 0.001) after G-CSF. Of note, four donors with low baseline vWF had a two- to three-fold increase after receiving G-CSF. GCSF had no impact on the platelet count, β-TG, PF-4, GMP-140 or PAC-1. The final% of platelet aggregation decreased from 73 ± 22% to 37 ± 26% after G-CSF (P < 0.001). We found a significant decrease in aPTT after G-CSF (29.9 ± 3.1 s to 28.3 ± 3.3 s; P = 0.004), but the PT was unaffected. In addition, we also observed a significant increase in TAT, F1 + 2 and TM, but not in tPA:Ag. Our data suggest that G-CSF may possibly induce a hypercoagulable state by increasing levels of FVIII:C and thrombin generation. In contrast to this information, we found reduced platelet aggregation after G-CSF administration. The clinical implications of these findings remain unclear and larger studies are definitely required.

KW - Granulocyte colony-stimulating factor

KW - Healthy peripheral blood stem cell donors

KW - Platelet activation

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0033008609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033008609&partnerID=8YFLogxK

M3 - Article

C2 - 10373063

AN - SCOPUS:0033008609

VL - 23

SP - 991

EP - 996

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -